Drugmakers: Our Take on Earnings
Sector director Damien Conover shares his key takeaways from Johnson & Johnson, Novartis, Glaxo, and Bristol Myers Squibb's reports.
We don't expect any changes to our fair value estimate for Johnson & Johnson (JNJ) after the firm reported second-quarter results largely in line with our expectations (after adjusting for divestitures) and slightly ahead of consensus expectations. We continue to view the stock as fairly valued and have factored in close to $3 billion in litigation charges for the opioid and talcum powder legal cases. Further, the firm's wide moat looks intact, especially following a research and development update for its drug unit that shows many promising molecules in areas with unmet medical need that should enable strong pricing power.
In the quarter, all three of J&J's major segments posted adjusted operational growth in the low- to mid-single-digit range. While the drug unit showed leadership growth in the quarter, the relative strength of this segment wasn't as robust as seen in the past few quarters as patent losses are weighing on the division, especially for cancer drug Zytiga. Nevertheless, the drug unit was able to post 4% operational growth and we expect continued steady growth for this division over the next several years, led by recently launched oncology and immunology drugs. Also, the firm's recent pipeline update in May increased our conviction in the division and led us to increase our fair value estimate by $4 per share to $134. These pipeline assets are tracking well, and we like the focus in oncology and rare diseases, where drug pricing is strong and development timelines can be short.
Damien Conover does not own shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.